By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast ...

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

The pharmaceutical giant just extended the lifespan of one of its top drugs.

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...